The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics
 
Vishnu Murthy
No Relationships to Disclose
 
Andrew Voter
No Relationships to Disclose
 
Kathleen Nguyen
No Relationships to Disclose
 
Martin S. Allen-Auerbach
No Relationships to Disclose
 
Sydney Caputo
No Relationships to Disclose
 
Elisa M. Ledet
No Relationships to Disclose
 
Opeoluwa Akerele
No Relationships to Disclose
 
Abuzar Moradi Tuchayi
No Relationships to Disclose
 
Courtney Lawhn Heath
No Relationships to Disclose
 
Michael Anthony Carducci
Honoraria - Remedica
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)
 
Martin Pomper
Employment - Johns Hopkins University
Leadership - Cancer Targeting Systems
Stock and Other Ownership Interests - Cancer Targeting Systems
Consulting or Advisory Role - Cancer Targeting Systems
Research Funding - Cancer Targeting Systems; Progenics
Patents, Royalties, Other Intellectual Property - FutureChem USA; Neuraly (Inst); Patents licensed to Cancer Targeting Systems, Progenics Phama and Advanced Accelerator Applications (Inst); Precision Molecular (Inst); Theraly (Inst)
 
Channing Judith Paller
Consulting or Advisory Role - AstraZeneca; Dendreon; Exelixis; Janssen Oncology; Omnitura
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Advanced Accelerator Applications; Aktis Oncology; Amgen; Jubilant Radiopharma; POINT Biopharma; RayzeBio
 
Lilja Solnes
Consulting or Advisory Role - Progenics
Research Funding - Advanced Accelerator Applications/Novartis; Progenics
 
Thomas A. Hope
Stock and Other Ownership Interests - Curium Pharma; RayzeBio
Honoraria - GE Healthcare
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Curium Pharma; Ipsen; ITM Isotope Technologies Munich; Lantheus Medical Imaging
Research Funding - Advanced Accelerator Applications (Inst); Clovis Oncology (Inst); GE Healthcare (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Philips Healthcare (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Oliver Sartor
No Relationships to Disclose
 
Andrei Gafita
No Relationships to Disclose